Drugs / Bendamustin
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01078142 | Feb 2010 → Sep 2017 | follicular lymphoma, mantle cell lymphoma | Georg Hess, MD | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06136351 | Nov 2023 → Nov 2027 expected | mantle cell lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05918276 | Jul 2023 → Dec 2024 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04934930 | Jan 2020 → Aug 2025 | follicular lymphoma | Meir Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00204620 | Mar 2002 → Dec 2006 | soft tissue sarcoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 2 | NCT00168922 | Feb 2001 → Dec 2006 | small cell lung carcinoma | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07575893 Background | Oct 2026 → Dec 2031 expected | classic Hodgkin lymphoma | New York Medical College | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06284122 Comparator | Jun 2024 → Nov 2028 expected | follicular lymphoma | The Lymphoma Academic Research Organisation | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bendamustin | “Drug: BG Bendamustin 70mg/m2, IV, d2\&d3 inC1, and then d1\&d2 inC2-6.” NCT05918276 ↗ |
| Known as | Ribomustin | “Bendamustin/Ribomustin” NCT00168922 ↗ |
| Route | Intravenous | “Bendamustin 70mg/m2, IV, d2\&d3 inC1, and then d1\&d2 inC2-6.” NCT05918276 ↗ |